excluded cases for which adjuvant therapy was “considered,” whereas our study categorized “considered” systemic therapy as guideline-concordant despite whether the treatment was received. Numerous clinical trials have demonstrated the benefit of specific
Search Results
Population-Based Study on Cancer Subtypes, Guideline-Concordant Adjuvant Therapy, and Survival Among Women With Stage I–III Breast Cancer
Mei-Chin Hsieh, Lu Zhang, Xiao-Cheng Wu, Mary B. Davidson, Michelle Loch, and Vivien W. Chen
Adjuvant Therapy for Soft Tissue Sarcoma
Scott M. Schuetze and Michael E. Ray
1995 ; 72 : 469 – 475 . 24 Zalupski MM Ryan JR Hussein ME Balker LH . Defining the role of adjuvant chemotherapy for patients with soft tissue sarcoma of the extremities . In: Salmon SE , ed. Adjuvant Therapy of Cancer VII. Philadelphia
Optimizing Endocrine Therapy for Breast Cancer
Amelia B. Zelnak and Ruth M. O'Regan
clearly defined. A meta-analysis of trials comparing ovarian ablation or suppression versus no adjuvant therapy showed improved outcomes; however, patients did not receive chemotherapy or tamoxifen. 10 Other trials investigating the role of ovarian
Adjuvant Endocrine Therapy in Hormone Receptor-Positive Postmenopausal Breast Cancer: Evolution of NCCN, ASCO, and St Gallen Recommendations
Robert W. Carlson, Clifford A. Hudis, and Kathy I. Pritchard
following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17 . J Natl Cancer Inst 2005 ; 97 : 1262 – 1271 . 22. Boccardo F Rubagotti A Puntoni M . Switching to anastrozole versus
HSR19-108: A Meta-Analysis of Randomized Controlled Trials (RCTs) for Efficacy and Safety of Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors (VEGF-TKIs) Adjuvant Therapy in High-Risk Renal Cell Cancer (RCC)
Irbaz Bin Riaz, Saad Ullah Malik, Muhammad Husnain, Qurat Ul Ain Riaz Sipra, Warda Faridi, Farva R. Gondal, Thanh Ho, Siddhartha Yadav, Zhen Wang, and Manish Kohli
alone because of its FDA approval. Heterogeneity was assessed with Cochrane Q statistic and was quantified with I 2 test. Risk for bias was assessed using the Cochrane Collaboration’s tool. Results: The 4 RCTs included 4,820 patients. Adjuvant therapy
Role of Radioactive Iodine for Adjuvant Therapy and Treatment of Metastases
Jacqueline Jonklaas
Normal thyrocytes and thyroid cancer cells are characterized by possession of a sodium iodide symporter. Radioiodine administration is a unique and powerful means of treating differentiated thyroid cancer because of the ability of thyroid cancer cells to concentrate beta-emitting radiolabeled iodine. Several manipulations, such as iodine depletion and thyroid hormone-stimulating hormone elevation, are used to enhance uptake of radiolabeled iodine by tumor cells. Adjuvant radioiodine therapy, given to patients without evidence of residual disease, enhances the sensitivity of subsequent surveillance and may decrease recurrence rates and mortality. However, its exact role in the management of low-risk patients merits further investigation. In contrast, radioactive iodine therapy used in patients with residual or metastatic disease clearly improves outcomes. Several studies show decreased recurrence and mortality rates in patients treated with radioiodine compared with those not receiving radioactive iodine. Adverse events from radioiodine therapy include salivary gland dysfunction, bone marrow suppression, and reproductive disturbances. Side effects of radioiodine therapy are generally greater when higher activities of radioiodine are used and may be transient or permanent. Secondary malignancies also may occur after radioiodine therapy. These side effects must be weighed against potential benefits, especially when radioactive iodine is used as adjuvant therapy. Stimulation of the expression of the sodium iodide symporter, or its introduction de novo into nonthyroid cells, is promising in treating poorly differentiated thyroid cancer and nonthyroid malignancies, respectively.
Adjuvant Therapy for Stage II Colon Cancer: Prognostic and Predictive Markers
Brian Vicuna and Al B. Benson III
for Medicare beneficiaries with stage II colon cancer . J Clin Oncol 2002 ; 20 : 3999 – 4005 . 3. Buyse M Piedbois P . Should Dukes' B patients receive adjuvant therapy? A statistical perspective [abstract] . Semin Oncol 2001 ; 28 ( 1
Primary Management of Early Stage Cervical Cancer (IA1-IB) and Appropriate Selection of Adjuvant Therapy
Heidi J. Gray
. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix . J Clin Oncol 2000 ; 18 : 1606 – 1613 . 13. Whitney CW
The Aromatase Inhibitors as Adjuvant Therapy for Hormone Receptor-Positive Breast Cancer
Jennifer A. Ligibel and Eric P. Winer
-negative breast cancer who have estrogen-receptor-positive tumors . N Engl J Med 1989 ; 320 : 479 – 484 . 4 Panel NIoHCD . National Institutes of Health Consensus Development Conference Statement: Adjuvant Therapy for Breast Cancer, November 1
Optimizing Adjuvant Therapy for Localized Colon Cancer and Treatment Selection in Advanced Colorectal Cancer
Axel Grothey and Alan P. Venook
Translational Research, and Chief, GI Oncology Clinical Trials Program, University of California, San Francisco. Dr. Venook discussed new recommendations for treating metastatic colon cancer. IDEA Informs Adjuvant Therapy for Localized Colon Cancer The
